Absolute Leukocyte Telomere Length in HIV-Infected and Uninfected Individuals: Evidence of Accelerated Cell Senescence in HIV-Associated Chronic Obstructive Pulmonary Disease

Joseph C. Y. Liu, Janice M. Leung, David A. Ngan, Negar F. Nashta, Silvia Guillemin, Marianne Harris, Viviane D. Lima, Soo-Jung Um, Yuexin Li, Sheena Tam, Tawimas Shaipanich, Rekha Raju, Cameron Hague, Jonathon A. Leipsic, Jean Bourbeau, Wan C. Tan, P. Richard Harrigan, Don D. Sin, Julio Montaner, S. F. Paul Man

1 Centre for Heart Lung Innovation, Vancouver, BC, Canada, 2 AIDS Research Program, St. Paul’s Hospital, Vancouver, BC, Canada, 3 Department of Family Medicine, Faculty of Medicine, University of British Columbia, Vancouver, Canada, 4 Division of HIV/AIDS, Department of Medicine, University of British Columbia, Vancouver, Canada, 5 BC Centre for Excellence in HIV/AIDS, St. Paul’s Hospital, Vancouver, BC, Canada, 6 Division of Pulmonary and Critical Care Medicine, Department of Medicine, Dong-A University, Busan, South Korea, 7 UBC Department of Medicine and Division of Respiratory Medicine, St. Paul’s Hospital, Vancouver, BC, Canada, 8 Department of Radiology and Diagnostic Imaging, St. Paul’s Hospital, Vancouver, BC, Canada, 9 Respiratory Epidemiology and Clinical Research Unit, Montreal Chest Institute, McGill University, Montreal, Quebec, Canada

☯ These authors contributed equally to this work.
* pman@providencehealth.bc.ca

Abstract

Combination antiretroviral therapy (cART) has extended the longevity of human immunodeficiency virus (HIV)-infected individuals. However, this has resulted in greater awareness of age-associated diseases such as chronic obstructive pulmonary disease (COPD). Accelerated cellular senescence may be responsible, but its magnitude as measured by leukocyte telomere length is unknown and its relationship to HIV-associated COPD has not yet been established. We measured absolute telomere length (aTL) in peripheral leukocytes from 231 HIV-infected adults. Comparisons were made to 691 HIV-uninfected individuals from a population-based sample. Subject quartiles of aTL were assessed for relationships with measures of HIV disease severity, airflow obstruction, and emphysema severity on computed tomographic (CT) imaging. Multivariable regression models identified factors associated with shortened aTL. Compared to HIV-uninfected subjects, the mean aTL in HIV-infected patients was markedly shorter by 27 kbp/genome (p<0.001); however, the slopes of aTL vs. age were not different (p=0.469). Patients with longer known durations of HIV infection (p=0.019) and lower nadir CD4 cell counts (p=0.023) had shorter aTL. Shorter aTL were also associated with older age (p=0.026), smoking (p=0.005), reduced forced expiratory volume in one second (p=0.030), and worse CT emphysema severity score (p=0.049). HIV-
infected subjects demonstrate advanced cellular aging, yet in a cART-treated cohort, the relationship between aTL and age appears no different from that of HIV-uninfected subjects.

Introduction

Combination antiretroviral therapy (cART) has lengthened the life expectancy of patients living with human immunodeficiency virus (HIV) [1]. Fewer HIV-infected individuals die from opportunistic infections and AIDS-related cancers [2]; instead, they now face chronic conditions normally associated with old age. Recently, studies have identified an increased prevalence of chronic obstructive pulmonary disease (COPD) within HIV-infected populations even after adjustment for age and smoking [3–5]. Clinical manifestations of COPD in the HIV population appear to be far more severe [4] and develop earlier than in HIV-uninfected individuals [6].

Disease models of accelerated cellular senescence apply well to HIV [7] and may explain the propensity towards age-associated conditions. In HIV, leukocyte telomere lengths, a marker of cellular aging, are comparatively shorter when measured against uninfected patients [8–10]. Telomeres are structures found at the ends of chromosomes, made up of repetitive TTAGGG DNA sequences and responsible for protecting genomic integrity. While telomere shortening occurs with each cell cycle, once a critical length is reached cell cycle arrest or apoptosis ensues [11]. Immune activation and microbial translocation are thought to drive telomere shortening in HIV [12], but the magnitude of telomere shortening that occurs upon infection with HIV remains unknown.

We postulate that accelerated cellular aging is a major driver for HIV-associated COPD and one that warrants further investigation. Although recent literature in HIV-uninfected cohorts has shown that telomere length is associated with COPD [13–15] and can predict mortality in COPD [16], whether telomere shortening is associated with more severe COPD specifically in HIV-infected populations is currently unknown.

The purpose of this study is twofold. First, we aim to quantify the magnitude of telomere shortening that occurs with HIV using a novel technique that measures absolute rather than relative telomere length [17–19]. This method, which standardizes quantitative polymerase chain reaction (qPCR) telomere length measurements, allows for cross-experimental and cross-study comparisons and may in future provide a universal high-throughput platform with which to measure telomere attrition. Accordingly, we measured absolute leukocyte telomere length (aTL) in a cohort of HIV-infected patients as well as in a large HIV-uninfected cohort. Second, we aim to investigate whether measures of COPD severity, including spirometry and extent of emphysema on lung imaging, are associated with aTL in the setting of HIV.

Materials and Methods

Study Populations

Participants were derived from a cohort of HIV-infected patients at St. Paul’s Hospital in Vancouver, British Columbia, Canada. The cohort was assembled as part of a prospective observational study of HIV-associated lung disease with enrollment taking place between August 2009 and June 2013 [6]. All cohort participants had serologically documented HIV-1 infection and were aged 19 years or older; COPD was not a specific inclusion criterion. Following informed consent, demographic data and clinical history were collected, and each participant had spirometry performed according to the American Thoracic Society/European Respiratory Society recommendations [20]. Individual forced expiratory volume in one second (FEV1)
measurements were expressed as a percentage of predicted (FEV1%Pred) using the NHANES III reference equation [21]. HIV-related clinical information, including laboratory data and cART history, were obtained through a linkage with the British Columbia Centre for Excellence in HIV/AIDS Drug Treatment Program database. The cut-off for successful viral suppression was determined to be <40 copies/mL [22]. Comorbidities such as hepatitis C, asthma, and cardiomyopathy were determined from the subject’s medical records. Moderate alcohol use was defined as the intake of ≥0.22 fl oz of alcohol per day [23]. Only the cross-sectional data derived from the participant’s first study visit were included in this analysis.

An HIV-uninfected control sample was derived from the Canadian Cohort of Obstructive Lung Disease (CanCOLD) study. CanCOLD is an ongoing, prospective longitudinal cohort study evaluating COPD progression. The cohort is originally derived from a larger cross-sectional population-based cohort (COLD) that evaluated COPD prevalence in 5,176 adults in nine Canadian cities (Vancouver, Calgary, Saskatoon, Montreal, Toronto, Quebec City, Ottawa, Kingston, and Halifax). These COLD participants were recruited by random digit dialing using census data from Statistics Canada with a mean participation rate of 75% [24]. From these participants, 1,140 non-COPD and COPD patients were enrolled for longitudinal follow-up to form the CanCOLD study cohort. The derivation of the longitudinal cohort for follow-up has been described in detail in a previous publication [25]. Enrollment in CanCOLD occurred between 2009 and 2013. Demographic data including age, sex, and smoking status and duration were available for this cohort, as were pre-bronchodilator spirometry measurements including FEV1 and FEV1%Pred, forced vital capacity (FVC), and FVC percent predicted (FVC %Pred). The data from the initial visit of the longitudinal cohort was used in this study. These data were collected at the same visit as the collection of venous blood samples. At the time of the current study, venous blood for telomere measurement was available in 691 consecutive individuals. The samples from the subjects with HIV and from the non-HIV population-based CanCOLD cohort were collected, processed and stored using the same protocol and analyzed in the same laboratory.

**Measurement of aTL in Peripheral Leukocytes**

Genomic DNA from peripheral leukocytes in HIV-infected participants and CanCOLD participants was harvested using the Qiagen DNeasy Blood & Tissue Kit (Qiagen, Venlo, the Netherlands). Effort was made to ensure samples had undergone only one freeze-thaw cycle before the extraction process. aTL was measured by quantitative PCR consistent with methods outlined by O’Callaghan and Fenech [17]. In brief, standard curves were generated from known quantities of synthesized oligomers of telomere (TEL) DNA [(TTAGGG)14] and single copy gene (36B4) DNA [CAGCAGTGGGAAGTTGTAATCCGTCTCCACAGACAGGCAAGCAAGGACACTTGTTTG7AACC G7GTGATGATAGAATGGG] (Sigma-Aldrich, St. Louis, MO). Sample telomere DNA length was then assessed based on the ratio of telomere DNA length to 36B4 DNA length as obtained from their respective standard curves. DNA from a short telomere cell line (HEK293) and a long telomere cell line (K562) (ATCC, Manassas, VA) were used as inter-experimental plate controls [26]. The telomere lengths measured using this method reflect an average length across the population of cells included in the sample. Samples were run in triplicate using the ABI ViiA 7 Real Time PCR System (Applied Biosystems, Foster City, CA). Both HIV and non-HIV samples were concurrently run on the same plate to avoid batch effects.

**Measurement of HIV RNA, CD4 Cell Count, and Inflammatory Biomarkers**

Blood samples were collected after an overnight fast using standard venipuncture methods, separated into their various components, and assayed for CD4 cell count and plasma HIV-1
RNA level (Roche Amplicor Ultrasensitive Assay and Roche Taqman Ultrasensitive Assay, Laval, Quebec, Canada) in the laboratory facilities of St. Paul’s Hospital. Plasma samples which had been stored at -80°C were thawed once for the measurements of C-reactive protein (CRP) and interleukin-6 (IL-6). All biomarker assays were measured in duplicate and the mean value of the duplicates for each sample was used for statistical analysis.

Computed Tomography (CT) Scans

Within one year of study enrollment, chest CT images were acquired in an unselected subset of the HIV-infected cohort, using a 64 detector CT scanner (VCT XT and Discovery HD 750 GE Healthcare, Waukasha, WI) under a modified clinical low effective dose protocol (1-0-mm slice thickness, 120 kVp, 215 mA, 0-6-second rotation time and pitch of 1-5, reconstructed using both high and intermediate spatial frequency reconstruction kernels). Two highly experienced radiologists (JAL and RR), blinded to spirometry and laboratory data, interpreted the CT images together to achieve consensus. Emphysema severity was quantified based on a modified method of Kazerooni et al. [27], also employed in the COPDGene study [28]. Individual scores for each of the five lobes plus the lingula were assessed as follows: 0 = absence of emphysema, 1 = 1–25% emphysema, 2 = 26–50% emphysema, 3 = 51–75% emphysema, and 4 = 76–100% emphysema. A total score was obtained by the summation of the scores of the five lobes and lingula (see S1 Fig for representative images). A total score of 0 indicated the absence of emphysema; a score of 1–2 indicated mild emphysema; 3–4 denoted moderate emphysema; and >4 indicated severe emphysema.

Statistical Analysis

We first divided the HIV cohort into quartiles of aTL. The baseline characteristics across the quartiles were compared using the Jonckheere-Terpstra trend test for continuous variables and the Cochran-Armitage test for dichotomous variables. Biomarkers were log-transformed to achieve normality. Collinearity, normality, and heteroscedascity were assessed to validate the linear regression models. To compare the respective aTL relationships with age between HIV and CanCOLD populations, a linear regression model was made using telomere length as a continuous dependent variable. Because of the availability of data on the CanCOLD subjects, only age, sex, smoking status, BMI, and FEV1%Pred were included as covariates.

To create the multivariable linear regression models with aTL as the output, important variables from univariate analyses (p<0.15) associated with aTL were included as candidates for the multivariable model. Then, a backward stepwise procedure was employed to build the multivariable linear regression model. The selection of variables was based on two criteria: Akaike Information Criterion (AIC) and Type I p-values. At each step during the backward stepwise multivariate analysis, the AIC value and the Type I p-value of each variable were recorded and the variable with the highest Type I p-value was dropped until we obtained the lowest AIC. These models were first created to examine the HIV only population to determine which factors may contribute to telomere shortening within HIV and secondly to the combined HIV and non-HIV population to determine the relative contribution of HIV itself to telomere shortening. To examine the robustness of the HIV only statistical model employed, secondary ordinal logistic regression models were performed using the quartiles of aTL as the output; however, since the results were similar to the linear regression models, only the results from the linear regression models are reported here.

All analyses were performed using JMP statistical software (version 10.0; SAS Institute, Cary, NC) and two-sided p-values <0.05 were considered significant.

Telomere Length and HIV-Associated COPD

PLOS ONE | DOI:10.1371/journal.pone.0124426 April 17, 2015 4/1
Ethics/Informed Consent

This study was conducted in accordance with the amended Declaration of Helsinki and received approval from the UBC Providence Health Care ethics review committee (No.H11-02713). All subjects provided written informed consent.

Results

Subjects

Fig 1 represents the flow chart for study inclusion (Fig 1A for the HIV-infected cohort and Fig 1B for the CanCOLD cohort). A total of 231 individuals formed the HIV-infected cohort. Baseline demographic and respiratory-related data for these subjects are shown in Table 1. The majority (91%) were male and the mean age was 49.6 years.

The HIV-infected cohort was segregated into quartiles based on aTL. Significant trends included older age (p = 0.026) and lower body mass index (BMI) (p = 0.011) in association with shorter aTL. Just over half of study participants were current smokers; participants with shorter aTL were more likely to have ever smoked (p = 0.005). Prior marijuana smoking (p = 0.015) was also associated with shorter aTL. Levels of inflammatory markers, CRP and IL-6, did not differ across quartiles of aTL (p = 0.711 and 0.626, respectively). Only two patients carried a diagnosis of cardiomyopathy and there were no cases of concurrent pulmonary hypertension.

Additionally, aTL were measured in 691 HIV-uninfected individuals from the CanCOLD cohort (see Table 2 for demographic information). After adjusting for sex, BMI, smoking, and FEV1%Pred, there was a significant negative correlation between telomere length and age, in both the CanCOLD and HIV groups (R² = 0.04, p < 0.001 and R² = 0.09, p = 0.030, respectively) (Fig 2). The slopes of aTL vs. age were similar between the two groups (p = 0.469) with both groups sharing a common slope of -0.713±0.155 kbp/genome/year (p<0.001). The difference in mean aTL between the CanCOLD and HIV populations (after adjustment for age, gender,
BMI, smoking pack-years, and FEV1%Pred) is shown in Fig 3. The mean±SEM atL for the CanCOLD and HIV populations were 150±3 and 123±4 kbp-genome, respectively (p < 0.0001).

Table 1. Baseline Characteristics of Study Participants, For All HIV+ Subjects and By Telomere Length Quartiles.

| Group                                      | All     | 1st (<110.2) | 2nd (110.2–132.4) | 3rd (132.5–155.8) | 4th (>155.9) | P-trend |
|--------------------------------------------|---------|---------------|--------------------|--------------------|--------------|---------|
| Telomere length (kbp/genome)              | 131.6 (30.0) | 92.7 (11.7)   | 120.5 (6.1)       | 144.1 (7.1)       | 169.8 (11.3) |         |
| No. of patients                            | 231     | 58            | 58                 | 58                 | 57           |         |
| No. of male patients (% of total)          | 211 (91%) | 55 (95%)      | 54 (93%)          | 52 (90%)          | 50 (88%)     | 0.135   |
| Age (years)                                | 49.6 (10.2) | 51.6 (9.2)   | 49.8 (10.0)       | 50.0 (10.8)       | 47.0 (10.6) | 0.026   |
| Body mass index (kg/m²)                    | 25.5 (4.6) | 24.6 (4.0)   | 25.3 (4.7)        | 25.9 (4.6)        | 26.6 (4.3)  | 0.011   |
| Ever smoker                                | 187 (81%) | 53 (91%)      | 48 (83%)          | 44 (76%)          | 42 (73%)     | 0.005   |
| Current Smoker                             | 128 (55%) | 30 (52%)      | 34 (59%)          | 35 (60%)          | 29 (51%)     | 0.984   |
| Smoking, pack-years                          | 29.7 (20.2) | 28.2 (17.6) | 30.5 (20.0)       | 29.9 (21.8)       | 23.8 (14.5) | 0.263   |
| Ever marijuana smoker                       | 140 (61%) | 40 (69%)      | 40 (69%)          | 31 (53%)          | 29 (51%)     | 0.015   |
| Ever crack smoker                           | 70 (30%)  | 21 (36%)      | 13 (22%)          | 20 (34%)          | 16 (28%)     | 0.649   |
| Ever IDU                                    | 81 (35%)  | 19 (33%)      | 24 (41%)          | 19 (33%)          | 19 (33%)     | 0.888   |
| Moderate-heavy alcohol use                  | 161 (70%) | 45 (78%)      | 39 (67%)          | 41 (71%)          | 36 (63%)     | 0.142   |
| CRP (µg/mL)                                | 2.5 (2.7) | 2.5 (2.8)     | 2.1 (2.3)         | 2.2 (2.6)         | 2.8 (2.9)    | 0.711   |
| IL-6 (pg/mL)                               | 2.5 (2.5) | 2.6 (2.4)     | 2.2 (2.3)         | 2.3 (2.4)         | 2.8 (2.8)    | 0.626   |
| Co-morbidities                              |          |               |                    |                    |              |         |
| Hepatitis C                                 | 51 (22%)  | 14 (24%)      | 14 (24%)          | 10 (17%)          | 13 (23%)     | 0.652   |
| Asthma                                     | 50 (23%)  | 10 (18%)      | 8 (15%)           | 17 (33%)          | 15 (27%)     | 0.083   |

Mean (SD) values are given for normally distributed variables, while dichotomous data are given as counts (% of total).

Abbreviation definition: IDU = injection drug use; CRP = C-reactive protein; IL-6 = interleukin-6.

†for current and ex-smokers.

doi:10.1371/journal.pone.0124426.t001

Telomere Length and HIV-Specific Variables

Associations between atL, HIV-specific variables, and AIDS-defining illnesses are shown in Table 3. Almost all study participants (94%) were on cART at the time of study enrollment with 156 (70%) patients achieving undetectable viral loads (<40 copies/mL). Longer time from HIV diagnosis to enrollment, an estimate of the duration of HIV infection, was associated with the shortest atL (p = 0.019). In addition, lower nadir CD4 cell counts were also associated with shorter atL (p = 0.023), while plasma viral loads >100,000 copies/mL at the time of HIV

Table 2. Characteristics of CanCOLD and HIV Subjects.

| Characteristic          | CanCOLD | HIV     | P-value |
|-------------------------|---------|---------|---------|
| No. of subjects         | 691     | 231     | <0.001  |
| Men (% of total)        | 345 (40%) | 211 (91%) | <0.001  |
| Age (years)             | 66.4 (9.6) | 49.3 (10.1) | <0.001  |
| Body mass index (kg/m²) | 27.7 (5.3) | 25.5 (4.6) | <0.001  |
| Ever smokers            | 438 (63%) | 187 (81%) | <0.001  |
| FEV1% predicted         | 89.6 (19.8) | 84.3 (22.1) | 0.001   |
| FEV1/FVC ratio (%)      | 69.0 (10.7) | 69.4 (17.4) | 0.016   |

Mean (SD) values are given for continuous variables, while dichotomous data are given as counts (% of total).

doi:10.1371/journal.pone.0124426.t002
diagnosis did not show a significant relationship. Although current CD4 cell counts tended to be lower in individuals with the shortest aTL, this did not achieve statistical significance ($p = 0.065$). Twenty-nine (13%) had prior *Pneumocystis jirovecii* pneumonia (PJP). However, a history of PJP was not statistically significant when comparing across aTL quartiles ($p = 0.098$).

**Telomere Length and COPD**

Respiratory variables for the HIV cohort are shown in Table 4. Lower FEV1, FEV1%Pred, and FEV1/FVC showed a significant trend with shorter aTL ($p = 0.030$, 0.029, and 0.037, respectively), while FVC and FVC %Pred did not. Among the 109 patients who underwent chest CT scanning, total CT emphysema scores ranged from 0 to 19 (S1 Table is provided to show demographic differences between those who underwent CT scanning and those who did not). A greater proportion of individuals with the shortest aTL had severe emphysema (CT emphysema score $>4$) ($p = 0.049$).

**Multivariable Analyses**

Multivariable analyses are shown in Tables 5 and 6. Within the HIV population only (Table 5), significant predictors of shorter aTL in a multivariate linear regression model included older age ($p = 0.010$), a history of smoking ($p = 0.010$), lower BMI ($p = 0.034$), and having a nadir CD4 cell count $\leq 350/\mu L$ ($p = 0.018$). Prior PJP infection, although included in the model, was not associated with aTL ($p = 0.065$).

In a multivariable linear regression analysis evaluating characteristics associated with shorter aTL for both the HIV and CanCOLD cohorts combined (Table 6), older age ($p < 0.001$), a history of smoking ($p = 0.006$), the presence of HIV ($p = 0.037$) remained
significant predictors of shorter aTL. FEV1%Pred did not remain a significant predictor of shorter aTL in the final model.

Discussion

In this study, we have quantified aTL shortening in an HIV-infected population, identifying a mean telomere length difference of approximately 27 kbp/genome when compared to a general population sample. Despite this considerable shortening, our population of cART-treated HIV-infected patients demonstrated a slope of aTL vs. age that was similar to that of an HIV-uninfected cohort. We speculate that aTL may have acutely shortened prior to study enrollment, perhaps at the time of acute HIV infection or during periods of the most severe
immunosuppression. Indeed, low nadir CD4 cell counts appear to place patients at highest risk for shortened aTL. Even in the absence of overt opportunistic infections, immunosuppression may be sufficient to cause accelerated aging, as we did not see an equivalent relationship between the presence of AIDS-defining conditions like PJP and aTL. Since the vast majority of our patients were receiving cART with adequate viral suppression and CD4 cell count

### Table 3. HIV-Related Clinical and Laboratory Data, For All HIV+ Subjects and By Telomere Length Quartiles.

| Group                              | All               | 1<sup>st</sup> (<110.2) | 2<sup>nd</sup> (110.2–132.4) | 3<sup>rd</sup> (132.5–155.8) | 4<sup>th</sup> (>155.9) | P-trend |
|------------------------------------|-------------------|--------------------------|-----------------------------|---------------------------|------------------------|---------|
| Telomere length (kbp/genome)       | 131.6 (30.0)      | 92.7 (11.7)              | 120.5 (6.1)                 | 144.1 (7.1)               | 169.8 (11.3)           |         |
| No. of patients                    | 231               | 58                       | 58                          | 58                        | 57                     |         |
| Time from HIV diagnosis to enrollment (months) | 143 (91)       | 149 (93)                 | 158 (97)                    | 154 (87)                  | 108 (81)               | 0.019   |
| Current cART use                   | 216 (94%)         | 55 (95%)                 | 53 (91%)                    | 58 (100%)                 | 50 (88%)               | 0.389   |
| NNRTI                              | 64 (27%)          | 19 (33%)                 | 16 (28%)                    | 15 (26%)                  | 14 (25%)               | 0.318   |
| NRTI                               | 204 (88%)         | 52 (90%)                 | 50 (86%)                    | 55 (95%)                  | 47 (82%)               | 0.500   |
| PI                                 | 132 (57%)         | 35 (60%)                 | 30 (52%)                    | 37 (64%)                  | 30 (53%)               | 0.708   |

At time of HIV diagnosis

| Plasma viral load >100,000 HIV RNA copies/mL | 120 (56%) | 34 (63%) | 28 (52%) | 29 (57%) | 29 (54%) | 0.450 |
| Nadir CD4 (cells/μL)                   | 209 (177) | 184 (168) | 182 (160) | 222 (196) | 246 (167) | 0.023 |
| Nadir CD4 <350 cells/μL                | 179 (85%) | 50 (93%)  | 47 (87%)  | 44 (86%)  | 38 (73%)  | 0.007 |

At study enrollment

| Plasma viral load <40 HIV RNA copies/mL | 156 (70%) | 39 (70%) | 40 (71%) | 42 (75%) | 35 (64%) | 0.605 |
| CD4 (cells/μL)                         | 529 (245) | 522 (258) | 481 (235) | 543 (198) | 576 (243) | 0.065 |
| CD4 <350 cells/μL                      | 51 (22%)  | 15 (26%)  | 15 (26%)  | 10 (18%)  | 11 (19%)  | 0.253 |
| Prior respiratory infection            | 98 (45%)  | 27 (48%)  | 22 (42%)  | 29 (55%)  | 20 (36%)  | 0.445 |
| PJP Infection                         | 29 (13%)  | 9 (16%)   | 9 (16%)   | 8 (14%)   | 3 (5%)    | 0.098 |
| Candidiasis of esophagus (% total)     | 16 (7%)   | 5 (9%)    | 3 (5%)    | 4 (7%)    | 4 (7%)    | 0.835 |
| Herpes Simplex (% total)               | 167 (72%) | 13 (22%)  | 20 (34%)  | 16 (28%)  | 15 (26%)  | 0.852 |

Abbreviation definitions: cART = combination antiretroviral therapy; PI = protease inhibitor; NNRTI = non-nucleoside reverse transcriptase inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; PJP = *Pneumocystis jirovecii* pneumonia.

doi:10.1371/journal.pone.0124426.t003

### Table 4. Respiratory Related Variables, For All HIV+ Subjects and By Telomere Length Quartiles.

| Group                              | All               | 1<sup>st</sup> (<110.2) | 2<sup>nd</sup> (110.2–132.4) | 3<sup>rd</sup> (132.5–155.8) | 4<sup>th</sup> (>155.9) | P-trend |
|------------------------------------|-------------------|--------------------------|-----------------------------|---------------------------|------------------------|---------|
| Telomere length (kbp/genome)       | 131.6 (30.0)      | 92.7 (11.7)              | 120.5 (6.1)                 | 144.1 (7.1)               | 169.8 (11.3)           |         |
| No. of patients                    | 231               | 58                       | 58                          | 58                        | 57                     |         |
| FEV1 (Liters)                      | 3.1 (0.9)         | 2.9 (0.9)                | 3.2 (1.0)                   | 3.1 (0.9)                 | 3.4 (0.9)              | 0.030   |
| FEV1%Pred                          | 84.3 (22.1)       | 79.0 (23.3)              | 84.9 (25.2)                 | 83.6 (20.6)               | 89.5 (19.2)            | 0.029   |
| FVC (Liters)                       | 4.4 (1.0)         | 4.2 (0.9)                | 4.5 (1.0)                   | 4.2 (1.1)                 | 4.5 (1.1)              | 0.377   |
| FVC %Pred                          | 91.8 (17.4)       | 90.0 (17.1)              | 93.1 (17.7)                 | 89.0 (17.0)               | 94.6 (17.6)            | 0.207   |
| FEV1/FVC (%)                       | 69.4 (17.4)       | 67.8 (15.0)              | 69.0 (17.4)                 | 71.5 (14.9)               | 73.0 (13.3)            | 0.037   |
| Total CT Emphysema Score           | 2.7 (4.1)         | 3.8 (4.7)                | 3.9 (5.5)                   | 1.2 (2.1)                 | 2.0 (2.6)              | 0.121   |
| CT Emphysema Score > 4             | 30 (13%)          | 12 (21%)                 | 8 (14%)                     | 5 (9%)                    | 5 (9%)                 | 0.049   |

Abbreviation definitions: FEV1 = forced expiratory volume in 1 second; FEV1%Pred = forced expiratory volume in 1 second percent predicted; FVC = forced vital capacity; FVC %Pred = forced vital capacity percent predicted; CT = computed tomography.

doi:10.1371/journal.pone.0124426.t004
normalization, the rate of telomere shortening may have stabilized. In fact, the findings of our study lead one to speculate that the early initiation of cART could abrogate the accelerated aging process and potentially avert adverse consequences such as COPD. Future studies assessing the impact of early cART initiation on the recent epidemic of age-related conditions in HIV would be a welcome addition to the field.

Our findings are in keeping with previous studies that have also demonstrated telomere shortening in HIV when compared to the general population [9,10]. However, we found different characteristics to be significantly associated with shortened aTL in our cohort of patients. Most recently, Zanet et al. found that patients with active hepatitis C and a peak HIV viral load ≥100,000 copies/mL were more likely to have short telomeres, two relationships that were not found in our study. As well, Pathai et al. found that low current CD4 cell counts were also associated with short aTL, whereas only nadir CD4 cell counts were significantly associated with aTL in our analysis. Differences in study populations may account for these discrepancies, as our population was mostly male as opposed to the predominantly female HIV-infected cohorts previously studied (females are generally believed to have longer telomeres than males [29,30]). In addition, a greater proportion of our patients were on cART in comparison to those in the two previous studies. Nonetheless, our study echoes a consistent theme that greater severity of HIV may be contributing to accelerated cellular aging.

The application of telomere biology to HIV-associated COPD yielded insight that accelerated aging may be an important driver of lung disease in this population, as we demonstrate that aTL is inversely related to lung function. This concurs with a recent study demonstrating that relative telomere length in peripheral blood mononuclear cells is also shortened in HIV patients with airflow obstruction and diffusion capacity impairment [31]. Although peripheral

### Table 5. Multivariable Regression Model: HIV Only.

| Linear Regression Model, HIV Only (Outcome: Telomere Length, Continuous) |
|---|
| **Unadjusted** | **Multivariable Model: R² = 0.14; p <0.01** |
| **Effect Estimate (SE)** | **P-value** | **β (SE)** | **Standardized β** | **P-value** |
| Ever smoker | -0.021 (0.007) | 0.002 | -6.418 (2.466) | -0.171 | 0.010 |
| Age (years) | -0.069 (0.022) | 0.002 | -0.507 (0.194) | -0.175 | 0.010 |
| Nadir CD4 <350 cells/μL | -0.020 (0.006) | 0.003 | -6.488 (2.726) | -0.158 | 0.018 |
| Body Mass Index (kg/m²) | 0.023 (0.010) | 0.018 | 0.916 (0.429) | 0.140 | 0.034 |

Abbreviations: SE = standard error

doi:10.1371/journal.pone.0124426.t005

### Table 6. Multivariable Regression Model: HIV and Non-HIV.

| Linear Regression Model, HIV and Non-HIV (Outcome: Telomere Length, Continuous) |
|---|
| **Unadjusted** | **Multivariable Model: R² = 0.05; p <0.01** |
| **Effect Estimate (SE)** | **P-value** | **β (SE)** | **Standardized β** | **P-value** |
| HIV Status (Infected) | -0.005 (0.002) | 0.004 | -10.406 (2.211) | -0.193 | <0.001 |
| Age (years) | -0.016 (0.009) | 0.058 | -0.755 (0.155) | -0.197 | <0.001 |
| Ever Smoker | -0.005 (0.002) | <0.001 | -4.769 (1.692) | -0.095 | 0.005 |
| FEV1%Pred | 0.037 (0.015) | 0.012 | 0.099 (0.076) | 0.044 | 0.190 |

Abbreviations: SE = standard error; FEV1: forced expiratory volume in 1 second

doi:10.1371/journal.pone.0124426.t006
leukocyte aTL reflects a systemic rather than local aging signal, these data suggest that cellular aging might also occur in lung-specific tissue. Recent evidence, for example, points to an excellent correlation between peripheral leukocyte and lung tissue telomere length in patients with α1-antitrypsin deficiency [32]. A similar relationship may exist in HIV-associated COPD, but requires further assessment. Our findings also support the known associations in HIV-uninfected patients between greater severity of airflow obstruction and shorter peripheral leukocyte [13–15] and lung tissue [33] telomere lengths. While HIV may be one trigger for accelerated aging, the combination of HIV and smoking, the latter of which demonstrated a significant association with shortened telomere lengths in our study, may prove to be a particularly potent dual hit to the telomere. Profound telomere shortening as a result may help incite the apoptosis that leads to the early development of COPD.

One of the strengths of our study is the use of a novel technique for measuring telomere length, a qPCR method that measures absolute rather than relative length. Unlike relative telomere length measurements in which quantification is dependent on the type of single copy gene standard chosen by each laboratory, absolute measurements allow for comparison across studies, providing a standardized method while still maintaining high volume capacity. aTL measurements are now becoming the preferred method for studying telomere length [18,19] and in future may be a more useful biomarker of aging given its standardization. The ability of aTL to predict which HIV-infected patients are at greatest risk for developing age-associated conditions such as COPD has yet to be determined, but our study suggests promise for future exploration.

Our study has several limitations, including the fact that we measured aTL in undifferentiated leukocytes. Measurements specifically performed in rapidly proliferating CD8+ T cells may have in fact revealed even shorter telomere lengths. If anything, our measurements are likely to overestimate aTL in our HIV cohort as a result. We did not in addition find any significant association between aTL and CD8+ T cell count or total leukocyte count (data not shown). Furthermore, aTL can only be measured in intact cells, raising the possibility that cellular environments prone to rapid apoptosis may not necessarily be reflected in the measurements obtained. As well, only half of our cohort was able to undergo chest CT scanning, somewhat limiting our ability to assess relationships between emphysema scoring and aTL. Finally, the majority of our HIV-infected cohort was male, so generalization to HIV-infected females may be limited. This is largely due to the fact that as a single-center study we were unable to capture many HIV-infected females who receive their HIV-related care at a different hospital in our city.

In summary, we demonstrate that although HIV infection is associated with a large and quantifiable shortening of telomeres, the declining slope of aTL vs. age may be attenuated in a population treated with cART. The use of a qPCR method to determine aTL may provide future studies in this field a common platform to compare a useful biomarker of aging. Furthermore, within HIV-infected individuals, the presence of COPD is associated with shorter telomeres, supporting an accelerated aging mechanism contributing to the development of COPD in HIV disease. Further studies should evaluate whether early cART initiation with subsequent suppression of HIV viral replication can normalize the rate of telomere attrition and prevent the onset of comorbidities such as COPD.

Supporting Information

S1 Fig. Representative Emphysema Score Images. A. Score 0 (absence of emphysema). B. Score 1 (1–25% emphysema). C. Score 2 (26–50% emphysema). D. Score 3 (51–75% emphysema). E. Score 4 (76–100% emphysema). (TIF)
S1 Table. Characteristics of those who underwent CT and those who did not.

(DOCX)

Author Contributions
Conceived and designed the experiments: JCYL JML PRH DDS SFPM JM. Performed the experiments: JCYL JML DAN SJU YL ST NFN TS. Analyzed the data: JCYL JML PRH DDS SFPM MH SG NFN RR CH JAL VDL. Contributed reagents/materials/analysis tools: JB WT. Wrote the paper: JML JCYL DDS SFPM.

References
1. Samji H, Cescon A, Hogg RS, Modur SP, Althoff KN, Buchacz K, et al. (2013) Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada. PLoS One 8: e681355. doi: 10.1371/journal.pone.0081355 PMID: 24367482
2. Smith C, Sabin CA, Lundgren JD, Thiebaut R, Weber R, Law M, et al. (2010) Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS 24: 1537–1548. doi: 10.1097/QAD.0b013e3283a0918 PMID: 20453631
3. Crothers K, Butt AA, Gibert CL, Rodriguez-Barradas MC, Crystal S, Justice AC, et al. (2006) Increased COPD among HIV-positive compared to HIV-negative veterans. Chest 130: 1326–1333. PMID: 17099007
4. Crothers K, Huang L, Goulet JL, Goetz MB, Brown ST, Rodriguez-Barradas MC, et al. (2011) HIV infection and risk for incident pulmonary diseases in the combination antiretroviral therapy era. Am J Respir Crit Care Med 183: 388–395. doi: 10.1164/rccm.201006-0836OC PMID: 20851926
5. Guaraldi G, Besutti G, Scaglioni R, Santoro A, Zona S, Guido L, et al. (2014) The Burden of Image Based Emphysema and Bronchiolitis in HIV-Infected Individuals on Antiretroviral Therapy. PLoS One 9: e109027 doi: 10.1371/journal.pone.0109027 PMID: 25354261
6. Leung JM, Liu JC, Mtambo A, Ngan D, Nashta N, Guillemi S, et al. (2014) The determinants of poor respiratory health status in adults living with human immunodeficiency virus infection. AIDS Patient Care STDS 28: 240–247. doi: 10.1089/apc.2013.0373 PMID: 24742270
7. Deeks SG, Phillips AN (2009) HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ 338: a3172. doi: 10.1136/bmj.a3172 PMID: 19171560
8. Effros RB, Allsopp R, Chiu CP, Hausner MA, Hirji K, Wang L, et al. (1996) Shortened telomeres in the expanded CD28−CD8+ cell subset in HIV disease implicate replicative senescence in HIV pathogenesis. AIDS 10: F17–22. PMID: 8828735
9. Zanet DL, Thorne A, Singer J, Maan EJ, Sattha B, Le Campion A, et al. (2014) Association Between Short Leukocyte Telomere Length and HIV Infection in a Cohort Study: No Evidence of a Relationship With Antiretroviral Therapy. Clin Infect Dis 58: 1322–1332. doi: 10.1093/cid/ciu051 PMID: 24457340
10. Pathai S, Lawn SD, Gilbert CE, McGuinness D, McGlynn L, Weiss HA, et al. (2013) Accelerated biological ageing in HIV-infected individuals in South Africa: a case-control study. AIDS 27: 2375–2384. doi: 10.1097/QAD.0b013e328363bf7f PMID: 23751258
11. Hodes RJ, Hathcock KS, Weng NP (2002) Telomeres in T and B cells. Nat Rev Immunol 2: 699–706. PMID: 12209138
12. Deeks SG, Verdin E, McCune JM (2012) Immuno senescence and HIV. Curr Opin Immunol 24: 501–506. doi: 10.1016/j.coi.2012.05.004 PMID: 22658763
13. Rode L, Bojesen SE, Weischer M, Vestbo J, Nordestgaard BG (2013) Short telomere length, lung function and chronic obstructive pulmonary disease in 46,396 individuals. Thorax 68: 429–435. doi: 10.1136/thoraxjnl-2012-202544 PMID: 23268483
14. Savale L, Chauvat A, Bastuji-Garin S, Marcos E, Boyer L, Maitre B, et al. (2009) Shortened telomeres in circulating leukocytes of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 179: 566–571. doi: 10.1164/rccm.200809-1398OC PMID: 19179485
15. Albrecht E, Sillanpaa E, Karrasch S, Alves AC, Codd V, Hovatta I, et al. (2014) Telomere length in circulating leukocytes is associated with lung function and disease. Eur Respir J 43: 983–992. doi: 10.1183/09031936.0046213 PMID: 24311771
16. Lee J, Sandford AJ, Connett JE, Yan J, Mui T, Li Y, et al. (2012) The relationship between telomere length and mortality in chronic obstructive pulmonary disease (COPD). PLoS One 7: e35567. doi: 10.1371/journal.pone.0035567 PMID: 22558169
17. O’Callaghan NJ, Fenech M (2011) A quantitative PCR method for measuring absolute telomere length. Biol Proced Online 13: 3. doi: 10.1186/1480-9222-13-3 PMID: 21369534

18. Fischer BM, Wong JK, Degan S, Kummarapurugu AB, Zheng S, Haridass P, et al. (2013) Increased expression of senescence markers in cystic fibrosis airways. Am J Physiol Lung Cell Mol Physiol 304: L394–400. doi: 10.1152/ajplung.00091.2012 PMID: 23316069

19. Cheung NK, Zhang J, Lu C, Parker M, Bahrami A, Tickoo SK, et al. (2012) Association of age at diagnosis and genetic mutations in patients with neuroblastoma. JAMA 307: 1062–1071. doi: 10.1001/jama.2012.228 PMID: 22416102

20. Miller MR, Crapo R, Hankinson J, Brusasco V, Burgos F, Casaburi R, et al. (2005) General considerations for lung function testing. Eur Respir J 26: 153–161. PMID: 15994402

21. Hankinson JL, Odencrantz JR, Fedan KB (1999) Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 159: 179–187. PMID: 9872837

22. Ribaudo HJ, Kuritzkes DR, Schackman BR, Acosta EP, Shikuma CM, Gulick RM (2006) Design issues in initial HIV-treatment trials: focus on ACTG A5095. Antivir Ther 11: 751–760. PMID: 17310819

23. Dawson D, Grant B, Chou P (1995) Gender differences in alcohol intake; Hunt W, Sakhari S, editors. Bethesda, MD: National Institute on Alcohol Abuse and Alcoholism Research.

24. Tan WC, Bourbeau J, FitzGerald JM, Cowie R, Chapman K, Hernandez P, et al. (2011) Can age and sex explain the variation in COPD rates across large urban cities? A population study in Canada. Int J Tuberc Lung Dis 15: 1691–1698. doi: 10.5588/ijtld.11.0211 PMID: 22118181

25. Bourbeau J, Tan WC, Benedetti A, Aaron SD, Chapman KR, Coxson HO, et al. (2014) Canadian Cohort Obstructive Lung Disease (CanCOLD): Fulfilling the Need for Longitudinal Observational Studies in COPD. COPD 11: 125–132. doi: 10.3109/15412555.2012.665520 PMID: 22433011

26. Fehrer C, Voglauer R, Wieser M, Pfister G, Brunauer R, Cioca D, et al. (2006) Techniques in gerontology: cell lines as standards for telomere length and telomerase activity assessment. Exp Gerontol 41: 648–651. PMID: 16677791

27. Kazerooni EA, Martinez FJ, Flint A, Jamadar DA, Gross BH, Spizarny DL, et al. (1997) Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. AJR Am J Roentgenol 169: 977–983. PMID: 9308447

28. Barr RG, Berkowitz EA, Bigazzi F, Bode F, Bon J, Bowler RP, et al. (2012) A combined pulmonary-radiology workshop for visual evaluation of COPD: study design, chest CT findings and concordance with quantitative evaluation. COPD 9: 151–159. doi: 10.3109/15412555.2012.654923 PMID: 22429093

29. Gardner M, Bann D, Wiley L, Cooper R, Hardy R, Nitsch D, et al. (2014) Gender and telomere length: systematic review and meta-analysis. Exp Gerontol 51: 15–27. doi: 10.1016/j.exger.2013.12.004 PMID: 24365661

30. Mayer S, Bruderlein S, Perner S, Waibel I, Holdenried A, Ciloglu N, et al. (2006) Sex-specific telomere length profiles and age-dependent erosion dynamics of individual chromosome arms in humans. Cyto- genet Genome Res 112: 194–201. PMID: 16484772

31. Fitzpatrick ME, Singh V, Bertoleit M, Lucht L, Kessinger C, Michel J, et al (2014) Relationships of pulmonary function, inflammation, and T-cell activation and senescence in an HIV-infected cohort. AIDS 28: 2505–2515. doi: 10.1097/QAD.0000000000000471 PMID: 25574956

32. Saferali A, Lee J, Sin DD, Rouhani FN, Brantly ML, Sandford AJ (2014) Longer Telomere Length in COPD Patients with alpha1-Antitrypsin Deficiency Independent of Lung Function. PLoS One 9: e95600. doi: 10.1371/journal.pone.0095600 PMID: 24763308

33. Tsuji T, Aoshiba K, Nagai A (2006) Alveolar cell senescence in patients with pulmonary emphysema. Am J Respir Crit Care Med 174: 886–893. PMID: 1688288